Source: Citybizlist

Aeglea: Aeglea BioTherapeutics Announces Reverse Stock Split

Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the... Read MoreThe post Aeglea BioTherapeutics Announces Reverse Stock Split appeared first on citybiz.

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

CEO

Update CEO

CEO Approval Rating

- -/100

Aeglea is a pharmaceutical company that researches and develops enzyme-based therapeutics for the treatment of cancer and rare genetic diseases.